ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017
Molecular Imaging of PARP.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging.ChemMedChem · 2026Article
- Recent advances in fluorescent probes for guided surgery of head and neck carcinomas.RSC advances · 2026Review
- Enhancing Veliparib PARP1 inhibitor stability against UVC degradationRSC advances · 2026Article
- Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging.European journal of nuclear medicine and molecular imaging · 2024Article
- PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.Current issues in molecular biology · 2024Review
- Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs.Molecules (Basel, Switzerland) · 2023Review
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.EJNMMI research · 2023Review
- Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use.Molecular imaging and biology · 2023Article
- Fully Automated, High-Dose Radiosynthesis of [Pharmaceuticals (Basel, Switzerland) · 2022Article
- In vivo molecular and single cell imaging.BMB reports · 2022Review
- Multiplexed imaging in oncology.Nature biomedical engineering · 2022Review
- Two experts and a newbie: [European journal of nuclear medicine and molecular imaging · 2022Article
- Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases.Frontiers in medicine · 2022Review
- A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.European journal of nuclear medicine and molecular imaging · 2021Article
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2021Review
- PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.Molecular pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The poly(adenosine diphosphate-ribose)polymerase (PARP) family of enzymes is an important factor in the cellular DNA damage response and has gained much attention for its role in many diseases, particularly cancer. Targeted molecular imaging of PARP using fluorescent or radiolabeled tags has followed on the success of therapeutic inhibitors and gained momentum over the past few years. This review covers PARP imaging from the very first imaging agents up to the current state of the technology, with a focus on the clinical applications made possible by these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.